The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced or metastatic esophageal cancer, providing a promising new therapeutic strategy.